Tremfya was launched by Janssen Biotech in late 2017 in the United States [1]. Its initial approval by the U.S. Food and Drug Administration (FDA) was for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1].
When did Tremfya become available in other countries?
Following its U.S. launch, Tremfya received approval from the European Medicines Agency (EMA) in September 2017, making it available in European Union member states shortly thereafter [2]. Canada also approved Tremfya in late 2017 [3].
What is Tremfya used to treat?
Tremfya is a prescription medication used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1]. It is also approved for the treatment of active psoriatic arthritis [4].
How does Tremfya work?
Tremfya works by targeting and blocking the IL-23 protein, which plays a key role in the inflammation associated with plaque psoriasis and psoriatic arthritis [1][4]. By inhibiting IL-23, Tremfya reduces inflammation and improves skin lesions in patients with psoriasis, and can help manage joint symptoms in psoriatic arthritis [1][4].
What are the potential side effects of Tremfya?
Common side effects of Tremfya include upper respiratory tract infections, headache, and injection site reactions [1]. More serious side effects can include increased risk of infections, allergic reactions, and rare cases of liver problems [1]. Patients are advised to discuss potential risks with their healthcare provider [1].
What is the patent situation for Tremfya?
Information regarding specific patent expiry dates for Tremfya is available through resources like DrugPatentWatch.com [5]. Patents protect the intellectual property of the drug, influencing market exclusivity and the potential for generic or biosimilar competition [5].
How does Tremfya compare to other psoriasis treatments?
Tremfya is a biologic medication that targets IL-23, differentiating it from other psoriasis treatments that may target different inflammatory pathways, such as TNF inhibitors or IL-17 inhibitors [4]. Clinical studies have shown Tremfya to be effective in achieving and maintaining skin clearance and improving joint symptoms for patients with moderate to severe plaque psoriasis and psoriatic arthritis [4]. Comparisons with other biologics often focus on efficacy, safety profiles, and administration schedules [4].